Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Posted inClinical Updates Diabetes & Endocrinology Specialties

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.
Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Posted inDiabetes & Endocrinology Specialties

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use in weight management.